Standard BioTools Inc expected to post a loss of 8 cents a share - Earnings Preview

Standard BioTools

09/08/2025 01:22

Standard BioTools Inc LAB.OQ LAB.O is expected to  show a rise in quarterly revenue when it reports  results on August 11 for the period ending June 30 2025

The South San Francisco California-based  company is expected to report a 7.0% increase in revenue to $39.824 million from $37.21 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Standard BioTools Inc is for a loss of 8 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Standard BioTools Inc is $1.93, about 32.2% above its last closing price of $1.31

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.08
-0.07
-0.07
Met
6.7
Dec. 31 2025
-0.06
-0.07
-0.09
Missed
-28.6
Sep. 30 2024
-0.09
-0.09
-0.07
Beat
22.2​
Jun. 30 2024
-0.09
-0.08
-0.12
Missed
-41.2
​​Mar. 31 2024
-0.13
-0.11
-0.27
Missed
-138.2
Dec. 31 2023
-0.13
-0.25
Missed
-92.3​
Sep. 30 2023
-0.12
-0.12
-0.27
Missed
-125
Jun. 30 2023
-0.21
-0.21
-0.22
Missed
-4.8

This summary was machine generated August 9 at 00:22 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)